CRISPR and the Rebirth of Synthetic Biology
- 2.3k Downloads
Emergence of novel genome engineering technologies such as clustered regularly interspaced short palindromic repeat (CRISPR) has refocused attention on unresolved ethical complications of synthetic biology. Biosecurity concerns, deontological issues and human right aspects of genome editing have been the subject of in-depth debate; however, a lack of transparent regulatory guidelines, outdated governance codes, inefficient time-consuming clinical trial pathways and frequent misunderstanding of the scientific potential of cutting-edge technologies have created substantial obstacles to translational research in this area. While a precautionary principle should be applied at all stages of genome engineering research, the stigma of germline editing, synthesis of new life forms and unrealistic presentation of current technologies should not arrest the transition of new therapeutic, diagnostic or preventive tools from research to clinic. We provide a brief review on the present regulation of CRISPR and discuss the translational aspect of genome engineering research and patient autonomy with respect to the “right to try” potential novel non-germline gene therapies.
KeywordsCRISPR Synthetic biology Genome engineering Gene therapy Bioethics Society
This research project was funded by the University of Basel and the ‘Swiss National Science Foundation’ under project Grant No. PDFMP3_137194/1.
- Collins, F. S. (2015). The NIH director. Statement on NIH funding of research using gene-editing technologies in human embryos. http://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nih-funding-research-using-gene-editing-technologies-human-embryos. Accessed 07 Dec 2015.
- Department of health and human services NIH. (2013). Revisions of the NIH guidelines for research involving recombinant or synthetic nucleic acid molecules. http://osp.od.nih.gov/sites/default/files/NIH_Guidelines_0.pdf. Accessed 07 Dec 2015.
- European Commission. (2014). Opinion on synthetic biology I definition. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_044.pdf. Accessed 07 Dec 2015.
- European Commission. (2015). Synthetic biology II—Risk assessment methodologies and safety aspects, opinion. http://ec.europa.eu/health/scientific_committees/emerging/docs/scenihr_o_048.pdf. Accessed 07 Dec 2015.
- European Council. (1997). Convention for the protection of human rights and dignity of the human being with regard to the application of biology and medicine: Convention on human rights and biomedicine. https://rm.coe.int/CoERMPublicCommonSearchServices/DisplayDCTMContent?documentId=090000168007cf98. Accessed 07 Dec 2015.
- European Council. (1998). Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of biotechnological inventions http://eur-lex.europa.eu/legal-content/EN/NOT/?uri=CELEX:31998L0044. Accessed 07 Dec 2015.
- European Council. (2009a). Directive 2001/20/ec of the european parliament and of the council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Commuinities, OJ L, 121, 34–44.Google Scholar
- European Council. (2009b). Commission directive 2009/120/EC of 14 September 2009 amending directive 2001/83/EC of the European Parliament and of the council on the community code relating to medicinal products for human use as regards advanced therapy medicinal products. Official Journal of the European Commuinities, L242, 3–12.Google Scholar
- European Council. (2009c). Contained use of genetically modified micro-organisms (GMMs) http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=URISERV:sa0015. Accessed 07 Dec 2015.
- European Medicines Agency. (2006). Concept paper on the development of a CHMP guideline on the non-clinical requirements to support early phase I clinical trials with pharmaceutical compounds. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500003979.pdf. Accessed 07 Dec 2015.
- Food and drug administration center for biologics evaluation and research. (1998). Guidance for industry: Guidance for human somatic cell therapy and gene therapy. http://www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/cellularandgenetherapy/ucm072987.htm#i. Accessed 07 Dec 2015.
- Greely, H. (2015). Law and biosciences blog of science, CRISPR-Cas9, and Asilomar. https://law.stanford.edu/2015/04/04/of-science-crispr-cas9-and-asilomar/. Accessed 07 Dec 2015.
- International bioethics committee of UNESCO (2015). (2015). Report of the IBC on updating its reflection on the human genome and human rights. http://unesdoc.unesco.org/images/0023/002332/233258E.pdf. Accessed 07 Dec 2015.
- Reardon, S. (2015). Leukaemia success heralds wave of gene-editing therapies. Accessed 06 Nov 2015.Google Scholar
- UNESCO. (1997). Universal declaration on the human genome and human rights. http://portal.unesco.org/en/ev.php-URL_ID=13177&URL_DO=DO_TOPIC&URL_SECTION=201.html. Accessed 07 Dec 2015.
- U.S Food and Drug Administration. (2006). Guidance for industry, investigators, and reviewers exploratory in studies. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf. Accessed 07 Dec 2015.